With the burgeoning interest in innovative treatments for type 2 diabetes and weight management, a direct assessment of Mounjaro and the dual GIP and GLP-1 receptor agonist has become critical. While both drugs function through related mechanisms – affecting GLP-1 and glucose-dependent insulinotropic polypeptide receptors – key differences in t… Read More